-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hematological tumors are one of the most common malignancies and an important disease
On September 26, 2022, Qian Pengxu's research group at the School of Basic Medicine/Liangzhu Laboratory of Zhejiang University and Chen Chunying, a researcher at the National Center for Nanoscience, published an online article entitled "Graphdiyne oxide nanosheets display selective anti-leukemia efficacy against DNMT3A-mutant AML.
"The research paper first reported the specific killing effect of graphyne oxide (GDYO) on DNMT3A mutant AML cells and related mechanisms
Mutation-induced gene dysfunction is usually the molecular basis for the onset of acute myeloid leukemia (AML), and epidemiological statistics indicate that about 20% of AML is a DNA methyltransferase 3A (DNMT3A) mutation, and DNMT3A mutations are usually associated
Compared with DNMT3A wild-type AML cells, DNMT3A mutant AML cells have high expression of adhesion-related genes and show a high adhesion phenotype
However, given that GDYO only has a selective effect on DNMT3A-mutant AML cells and is not universally active for all cells tested, there are other cell-specific factors that affect GDYO's biological activity
Wang Qiwei, a postdoctoral fellow at Zhejiang University School of Basic Medicine/Liangzhu Laboratory, is the first author of this paper, and Liu Ying, associate researcher Wang Hui, and Jiang Penglei and Qian Wenchang, postdoctoral fellows of Liangzhu Laboratory, are the first authors
